KalVista Pharmaceuticals's total assets for Q3 2025 were $275.99M, an increase of 71.60% from the previous quarter. KALV total liabilities were $130.87M for the fiscal quarter, a 387.60% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.